N/A N=61 Medication-overuse Headache (MOH): Withdrawal or Use of Preventative Medications Directly?
Headache
Primary: Headache Days — 7.2; 4.2; 1.6 days/month — p=0.056
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
Substance-Related Disorders
Primary: OOWS Score — 3.5; 1.0; 0 units on a scale (OOWS Scale) — p=0.0001
Phase 2 N=49 Acamprosate to Reduce Symptoms of Alcohol Withdrawal
Alcohol-Related Disorders · Alcohol Dependence · Alcoholism
Primary: Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 — 1.256772; 1.294178 Ratio of glutamate to creatine
Phase 2 N=35 Studying Amphetamine Withdrawal in Humans
Methamphetamine Dependence
Primary: Measure of Methamphetamine Withdrawal — 3.7283; 10.056 units on a scale
N/A N=15 Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers
Substance-Related Disorders
Primary: Brain Regions With Increases or Decreases in Amplitude of Low Frequency Fluctuations (ALFF) Associated With Ondansetron Administration — 0.519; 0.562; 0.478; 0.486…
N/A N=60 Medication-overuse Headache: 4 Years Follow up
Medication Overuse Headache
Primary: Change in Headache Days/Month After 4 Years Compared to Baseline — 6.6 headache days/month
N/A N=14 Effect of Ondansetron for Withdrawal Symptoms
Substance Withdrawal Syndrome
Primary: Change in Withdrawal Symptoms With Placebo and With Ondansetron — -22.08; -42.71 Percent change
Phase 3 N=53 Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
Substance Withdrawal Syndrome
Primary: Subjective Opioid Withdrawal Total Adjective Score — 5.8; 7.7; 6.9 units on a scale
Phase 4 N=5 An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute Headache
Pain
Primary: Change in Pain Score at 60 Minutes — 4; 5 score on a scale
Phase 2 N=70 Treatment for Cannabis Withdrawal and Dependence
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg
N/A N=133 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Opioid Withdrawal · Physical Dependence
Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87
Phase 2 N=103 Medications Development for Drug Abuse Disorders
Opioid Related Disorders · Opioid Dependence · Opioid Addiction
Primary: Mean Ratings on Clinical Opiate Withdrawal Scale (COWS) Measure of Withdrawal During Double-blind Taper (7-days) and Post-taper (7-days) Period. — 7.79; 8.41; 8.28; 6.16…
N/A N=106 Cocaine Withdrawal and Pharmacotherapy Response
Cocaine Dependence · Opiate Dependence
Primary: Percent Days Abstinent From Cocaine - Self Report — 72.9; 72.9; 59.3 percentage of days — p=.10
N/A N=70 A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.
Headache
Primary: Number of Participants With Adequate Relief of Headache as a Measure of Efficacy — 34; 32 Participants — p=0.14
Phase 3 N=205 Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Migraine
Primary: Persistent Headache Pain Free at 24 Hours — 26; 19 Participants
N/A N=29 Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
Substance Withdrawal Syndrome
Primary: Description of Signs and Symptoms of OIWS in Patients Who Scored Positive for Withdrawal Syndrome (OIWS) According to Diagnostic and Statistical Manual of Mental…
Phase 2 N=25 Improving Buprenorphine Detoxification Outcomes With Isradipine
Opioid Dependence
Primary: Change Over Time in Illicit Opioid Use Via Urine Toxicology Screens During Buprenorphine Taper (Wks 5-6) — -1.25; -0.36 opioid-positive urine — p=.42
Phase 2 N=12 A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
Opioid Abuse · Opioid Dependence
Primary: Mean Peak Opioid Withdrawal Assessed by the Clinical Opiate Withdrawal Scale (COWS) — 12.6; 1.3 units on a scale
Phase 2 N=52 Ibudilast and Withdrawal-Related Dysphoria
Alcohol Use Disorder
Primary: Negative Affect — 2.91; 2.47 units — p=.62
Phase 2 N=31 Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches
Delayed Alcohol Induced Headache
Primary: Headache Severity 2 Hours Post Treatment — 2.18; 2.09; 0.85; 1.17 units on a scale
Phase 2 N=3 Oral Cannabidiol for Opioid Withdrawal
Opioid Withdrawal · Opioid Craving · Opioid Use Disorder
Primary: Safety as Assessed by Number of Adverse Events — 4; 5 Adverse Events
Phase 4 N=401 Comparing Naproxen to Sumatriptan for Emergency Headache Patients
Migraine · Tension-type Headache · Primary Headache Disorder
Primary: Numerical Rating Scale — 4.1; 4.3 units on a scale
Phase 2 N=44 Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal
Opioid-Related Disorders
Primary: Subjective Opioid Withdrawal Scale Score (SOWS) — 16; 4; 24 units on a scale
Phase 4 N=16 Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage
Aneurysmal Subarachnoid Hemorrhage
Primary: Average Numeric Pain Score — 5.2; 5.8 score on a scale — p=0.7
Phase 3 N=160 Metoclopramide for Post Traumatic Headache
Post-Traumatic Headache
Primary: 0-10 Pain Scale on Which 0 = no Pain and 10= the Worst Pain Imaginable — 5.2; 3.8 units on a scale
Early Phase 1 N=8 Progesterone for Cannabis Withdrawal
Cannabis Use Disorder · Cannabis Withdrawal
Primary: Change in Salivary Progesterone Level — 237.86; 97.87 pg/ml
N/A N=8 Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study
Methamphetamine Dependence · Methamphetamine Withdrawal
Primary: Methamphetamine Selective Severity Assessment (MSSA) — 48.2 "units on a scale" — p=<0.05
N/A N=69 Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
Substance Withdrawal Syndrome
Primary: Number of Participants That Received Rescue Medication for Withdrawal Symptoms Within 1 Hour — 9; 19 Participants
N/A N=759 IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
Headache Disorders, Primary · Migraine With Aura · Migraine Without Aura
Primary: Percentage of Patients With Significant Pain Reduction — 90.3 percentage of participants
Phase 4 N=123 Metoclopramide Versus Ketorolac for Tension-type Headache
Headache
Primary: Change in Pain Score — 3.8; 5.1 units on a scale